Clinical Trial Update: QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) [Phase 2]

View source ↗

Summary

A Phase 2 trial of QL1706 in combination with Olaparib for previously treated HER2-negative breast cancer patients with homologous recombination deficiency is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)
• QL1706

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency | Phase 2 | Status: NOT_YET_RECRUITING